These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27296265)

  • 1. [Resistant cytomegalovirus infection in related donor kidney allograft recipients].
    Goryainov VA; Kaabak MM; Babenko NN; Platova EN; Aganesov AG; Morozova MM; Panin VV
    Ter Arkh; 2016; 88(6):73-76. PubMed ID: 27296265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
    Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
    Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
    Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
    Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation.
    Lapidus-Krol E; Shapiro R; Amir J; Davidovits M; Steinberg R; Mor E; Avitzur Y
    Pediatr Transplant; 2010 Sep; 14(6):753-60. PubMed ID: 20477976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients.
    Luan FL; Chopra P; Park J; Norman S; Cibrik D; Ojo A
    Transplant Proc; 2006 Dec; 38(10):3673-5. PubMed ID: 17175363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
    van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
    Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation.
    Aigner C; Jaksch P; Winkler G; Czebe K; Taghavi S; Marta G; Klepetko W
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):480-4. PubMed ID: 16091875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction.
    Luan FL
    Transplant Proc; 2013; 45(1):175-7. PubMed ID: 23267799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
    Höcker B; Zencke S; Krupka K; Fichtner A; Pape L; Dello Strologo L; Guzzo I; Topaloglu R; Kranz B; König J; Bald M; Webb NJ; Noyan A; Dursun H; Marks S; Yalcinkaya F; Thiel F; Billing H; Pohl M; Fehrenbach H; Bruckner T; Tönshoff B
    Transplantation; 2016 Apr; 100(4):862-70. PubMed ID: 26736017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss.
    Andrei G; Van Loon E; Lerut E; Victoor J; Meijers B; Bammens B; Sprangers B; Gillemot S; Fiten P; Opdenakker G; Lagrou K; Kuypers D; Snoeck R; Naesens M
    Antiviral Res; 2019 Aug; 168():203-209. PubMed ID: 31212020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
    Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
    Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed-onset primary cytomegalovirus disease after liver transplantation.
    Arthurs SK; Eid AJ; Pedersen RA; Dierkhising RA; Kremers WK; Patel R; Razonable RR
    Liver Transpl; 2007 Dec; 13(12):1703-9. PubMed ID: 18044717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and clinical impact of cytomegalovirus infection and disease in renal transplantation: ten years of experience in a single center.
    Giakoustidis D; Antoniadis A; Fouzas I; Sklavos A; Giakoustidis A; Ouzounidis N; Gakis D; Koubanagiti K; Myserlis G; Tsitlakidis A; Gerogiannis I; Papagiannis A; Christoforou P; Deligiannidis T; Solonaki F; Imvrios G; Papanikolaou V
    Transplant Proc; 2012 Nov; 44(9):2715-7. PubMed ID: 23146502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valganciclovir administration to kidney donors to reduce the burden of cytomegalovirus and Epstein-Barr virus transmission during transplantation.
    Verghese PS; Schmeling DO; Knight JA; Matas AJ; Balfour HH
    Transplantation; 2015 Jun; 99(6):1186-91. PubMed ID: 25489844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
    Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.